Journal List > J Korean Ophthalmol Soc > v.53(10) > 1009194

TOOLS
Rim, Park, and Yoon: Hormone Replacement Therapy and Eye Diseases: KNHANES IV
Original Article
Journal of the Korean Ophthalmological Society

Journal of the Korean Ophthalmological Society 2012; 53(10): 1445-1450.

Published online: 17 October 2012

DOI: https://doi.org/10.3341/jkos.2012.53.10.1445

Hormone Replacement Therapy and Eye Diseases: KNHANES IV

Hyung Taek Rim, MD, Sun Young Park, MD, Jin Sook Yoon, MD

Department of Ophthalmology, Yonsei University College of Medicine, Institute of Vision Research, Seoul, Korea.

Address reprint requests to Jin Sook Yoon, MD. Institute of Vision Research, Department of Ophthalmology, Severance Hospital, #50 Yonse-ro, Seodaemun-gu, Seoul 120-752, Korea. Tel: 82-2-2228-3570, Fax: 82-2-312-0541, yoonjs@yuhs.ac

Received 10 March 2012       Accepted 10 September 2012

Copyright © 2012 The Korean Ophthalmological Society

Abstract

Purpose

To identify the association between hormone replacement therapy and eye diseases.

Methods

The fourth Korea National Health and Nutrition Examination Survey (KNHANES IV) is a nationwide survey. The study included 5,808 females who completed the KNHANES IV. The prevalence of eye disease of adjusted mean using linear regression analysis between the subjects who had hormone replacement therapy and those who did not have the therapy was analyzed.

Results

Among the 5,808 females, 480 (8.3%) received hormone replacement therapy. The adjusted prevalence of myopia was 44.5% (95% CI, 38.1-51.2) in the subjects who received hormone replacement therapy, and 54.4% (95% CI, 52.6-56.1) in those who did not have the therapy. The adjusted prevalence of hyperopia was 7.7% (95% CI, 5.5-10.6) in subjects who received hormone replacement therapy and 4.5% (95% CI, 3.8-5.3) in those who did not have the therapy. The adjusted prevalence of pterygium was 2.1% (95% CI, 1.3-3.3) in the subjects who received hormone replacement therapy and 3.3% (95% CI, 2.7-4.0) in those who did not have the therapy. All the results were statistically significant with a p-value <0.05. The adjusted prevalence of diabetic retinopathy was 5.6% (95% CI, 1.4-19.8) in the subjects who received hormone replacement therapy and 16.7% (95% CI, 13.0-21.2) in those who did have the therapy. The p-value was 0.053, which is marginally statistically significant.

Conclusions

The adjusted prevalence of myopia, pterygium, and diabetic retinopathy in the subjects who received hormone replacement therapy was low, although hyperopia was statistically significantly high.

Keywords: Eye diseases, Hormone replacement therapy, KNHANES IV, Socio-demographic factors

Figures and Tables

Figure 1
Unadjusted and adjusted mean after adjusting age, sex, income, education, and residential area in subjects receive hormone replacement therapy and those not receive. HRT: subjects receive hormone replacement therapy; non-HRT: subjects not receive hormone replacement therapy.
jkos-53-1445-g001
Table 1
Charateristic of study population (n = 5,808)
jkos-53-1445-i001

*To derive income per adult equivalent, we defined as household 'income / square root of person'.

References

1. Rockman CB, Maldonado TS, Jacobowitz GR, et al. Hormone replacement therapy is associated with a decreased prevalence of peripheral arterial disease in postmenopausal women. Ann Vasc Surg. 2012. 26:411–418.
2. Sator MO, Akramian J, Joura EA, et al. Reduction of intraocular pressure in a glaucoma patient undergoing hormone replacement therapy. Maturitas. 1998. 29:93–95.
3. Freeman EE, Munoz B, Schein OD, West SK. Incidence and progression of lens opacities: effect of hormone replacement therapy and reproductive factors. Epidemiology. 2004. 15:451–457.
4. Younan C, Mitchell P, Cumming RG, et al. Hormone replacement therapy, reproductive factors, and the incidence of cataract and cataract surgery: the Blue Mountains Eye Study. Am J Epidemiol. 2002. 155:997–1006.
5. Kanthan GL, Wang JJ, Burlutsky G, et al. Exogenous oestrogen exposure, female reproductive factors and the long-term incidence of cataract: the Blue Mountains Eye Study. Acta Ophthalmol. 2010. 88:773–778.
6. Klein BE, Klein R, Moss SE. Exogenous estrogen exposures and changes in diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 1999. 22:1984–1987.
7. Erdem U, Muftuoglu O, Goktolga U, Dagli S. Effect of hormone replacement therapy in women on ocular refractive status and aberrations. J Refract Surg. 2007. 23:567–572.
8. Edwards DR, Gallins P, Polk M, et al. Inverse association of female hormone replacement therapy with age-related macular degeneration and interactions with ARMS2 polymorphisms. Invest Ophthalmol Vis Sci. 2010. 51:1873–1879.
9. Freeman EE, Munoz B, Bressler SB, West SK. Hormone replacement therapy, reproductive factors, and age-related macular degeneration: the Salisbury Eye Evaluation Project. Ophthalmic Epidemiol. 2005. 12:37–45.
10. Smith W, Mitchell P, Wang JJ. Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. Aust N Z J Ophthalmol. 1997. 25:Suppl 1. S13–S15.
11. Erdem U, Ozdegirmenci O, Sobaci E, et al. Dry eye in post-menopausal women using hormone replacement therapy. Maturitas. 2007. 56:257–262.
12. Mathers WD, Dolney AM, Kraemer D. The effect of hormone replacement therapy on the symptoms and physiologic parameters of dry eye. Adv Exp Med Biol. 2002. 506:1017–1022.
13. Barney NP. Can hormone replacement therapy cause dry eye? Arch Ophthalmol. 2002. 120:641–642.
14. Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA. 2001. 286:2114–2119.
15. Moon JH, Jung JW, Shin KH, Paik HJ. Effect of hormone replacement therapy on dry eye syndrome in postmenopausal women: A prospective study. J Korean Ophthalmol Soc. 2010. 51:175–179.
16. Yoon KC, Mun GH, Kim SD, et al. Prevalence of eye diseases in South Korea: data from the Korea national health and nutrition examination survey 2008-2009. Korean J Ophthalmol. 2011. 25:421–433.
17. Huang KE, Baber R. Updated clinical recommendations for the use of tibolone in Asian women. Climacteric. 2010. 13:317–327.
18. Namkung J, Chung YJ, Ha JE, et al. The survey on Korean menopausal women's behavior and perception of hormone therapy. J Korean Soc Menopause. 2011. 17:142–149.
19. Maclennan AH, Wilson DH, Taylor AW. Hormone replacement therapy: Prevalence, compliance and the 'healthy women' notion. Climacteric. 1998. 1:42–49.
20. Connelly MT, Richardson M, Platt R. Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990-1995. J Gen Intern Med. 2000. 15:542–550.
21. Sharma S, Rekha W, Sharma T, Downey G. Refractive issues in pregnancy. Aust N Z J Obstet Gynaecol. 2006. 46:186–188.
22. Affinito P, Di Spiezio Sardo A, Di Carlo C, et al. Effects of hormone replacement therapy on ocular function in postmenopause. Menopause. 2003. 10:482–487.
23. Ishioka M, Shimmura S, Yagi Y, Tsubota K. Pterygium and dry eye. Ophthalmologica. 2001. 215:209–211.
24. Rajiv , Mithal S, Sood AK. Pterygium and dry eye--a clinical correlation. Indian J Ophthalmol. 1991. 39:15–16.
25. Glacet-Bernard A, Kuhn D, Soubrane G. Ocular complications of hormonal treatments: oral contraception and menopausal hormonal replacement therapy. Contracept Fertil Sex. 1999. 27:285–290.
26. Arroyo J. Age-related eye diseases: impact of hormone replacement therapy, and reproductive and other risk factors,. by K. K. Snow and J. M. Seddon. Int J Fertil Womens Med 45:301-13, 2000. Surv Ophthalmol. 2003. 48:236–237.
27. Sator MO, Joura EA, Frigo P, et al. Hormone replacement therapy and intraocular pressure. Maturitas. 1997. 28:55–58.
28. Uncu G, Avci R, Uncu Y, et al. The effects of different hormone replacement therapy regimens on tear function, intraocular pressure and lens opacity. Gynecol Endocrinol. 2006. 22:501–505.
TOOLS
Similar articles